Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market cap$300M–$10B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Saturday, October 17, 2026· 3809 stock ideas· 217 writers·
17,412 views· 8,067 clicks

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

BMBL $783M
TSOH Investment Research 4 clicks

From X

@kevin__mak

Kevin Mak on X

$NKTR Lots of funky action in this name the past few days, some specific to the ongoing court case and some from bio as a whole. Let's unpack it. The jury note, paraphrased as "Is there a difference between breach + $1 and no breach + $0?", spooked the market and sent the stock down sharply. Two sides to this. First, the note is informative, but only a little. It tells us at least one juror sees the $0/$1 outcome as part of their possible resolution space. Where I think the market (or at least fintwit) got it wrong is treating the note as the voice of the entire jury. It could reflect the whole panel, or it could be a single juror's question. It doesn't even tell us direction: it could come from a juror looking for a way to find breach despite doubting the damages case. The price action implied the whole jury is now choosing between $0 and $1, which I think is a big overread. Second, this is NKTR: a retail/fintwit-heavy, relatively illiquid SMID-cap biotech that moves 5% on a random Tuesday with no news. A 10% move on this headline looks extreme, but near-term price action here mostly reflects value-agnostic traders playing local news and liquidity flow, not a considered repricing of long-term value. The bigger picture: the case is largely a distraction from the real value, which is Rezpeg. I'm not a biotech expert, but the sell side and most biotech specialists I respect see it as a likely viable commercial product that's underpriced here. If anything, the case matters mainly as an overhang. An uncertain $0-to-$1B+ claim is hard for any acquirer or partner to price, so resolution in almost any direction clears the path for corporate action. The distraction is creating the opportunity. Disclosure: Creek Drive and its affiliated funds holds a long position in NKTR. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Modine Deep Dive

Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…

MOD $9.2B
CV's Substack 14 clicks

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI…

SOLS $9.7B
Yet Another Value Podcast 85 clicks
TY · long

Tri-continental CORP

Tri-Continental Corp is presented as a long investment-grade fixed-income idea for portfolios with limited liquidity and diversification.

TY $1.8B
Value Investors Club

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

LQDA $3.1B
Trade Ideas Flow 4 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Thursday, October 15 61 stock ideas
  • Is The Market Turning The Page? WHAT ARE WE DOING? “Contrarians At The Gate”
  • Breaking: The Offshore Monopoly Is Legal Now! Cannibal Stocks
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 50 of 233

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick